March 28, 2019
Daiichi Sankyo said on March 27 that the first patient has been dosed in an Asian PIII trial for its pain treatment mirogabalin for the treatment of neuropathic pain of post-spinal cord injury. The placebo-controlled trial, dubbed AMELA, will be...read more